Clinical Significance of Circulating Tumor Cells in Advanced Gastric Cancer

Clinical Significance of Circulating Tumor Cells in Predicting the Therapeutic Efficacy of Zolbetuximab for HER2-Negative Gastric Cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1071250066

Enrollment

Registered

2025-09-04

Start date

2025-09-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed gastric adenocarcinoma diagnosed by pathological examination of endoscopic biopsy and/or surgical specimens. 2. Patients with stage IV advanced gastric cancer or recurrent gastric cancer. 3. HER2-negative status must be confirmed. 4. Patients aged 18 years or older at the time of consent, regardless of gender. 5. Patients receiving care either as inpatients or outpatients. 6. Patients diagnosed with gastric cancer and received medical care between April 1, 2025, and March 31, 2027.

Exclusion criteria

Exclusion criteria: 1. Patients with synchronous multiple primary cancers. 2. Cases in which adenocarcinoma is not confirmed by pathological examination. 3. Patients who lack the capacity to provide informed consent. 4. Any other cases deemed inappropriate for study participation by the attending physician.

Design outcomes

Primary

Measure	Time frame
The Relationship of CLDN Expression Between Primary Tumors and Circulating Tumor Cells in the Blood	—

Secondary

Measure	Time frame
The Relationship Between CLDN Expression in Circulating Tumor Cells and the Therapeutic Efficacy of Zolbetuximab-Based Chemotherapy	—

Contacts

Public ContactTakaaki Arigami

Kagoshima University Hospital

arigami@m.kufm.kagoshima-u.ac.jp+81-99-275-5361

Outcome results